Q-omics provides the consensus-scored MTHFD2L profile across patient tissues and cancer cell-line models. MTHFD2L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MTHFD2L is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MTHFD2L RNA expression shows 20,286 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where MTHFD2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTHFD2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTHFD2L survival associations across molecular data types. MTHFD2L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTHFD2L RNA expression–survival associations across cancer types. High MTHFD2L expression shows unfavorable associations in UVM, ACC and KIRC, but favorable associations in LUAD, READ and BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MTHFD2L RNA expression.
This table summarizes MTHFD2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTHFD2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTHFD2L shows lower tumor expression in KIRC, LIHC, KICH and KIRP and higher tumor expression in HNSC and UCEC. The KIRC box plot shows higher MTHFD2L RNA expression in normal versus tumor tissue (log2 FC = −0.835, t-test p < 0.001).
This table shows molecular features associated with MTHFD2L in patient tissues and cancer cell lines. In patient samples, MTHFD2L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTHFD2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
